Lung Diseases Cies Search Engine [selected websites]


Blog Archive

Oct 9, 2008

Neotropix : Expansion of On-going Clinical Trial for Adult Neuroendocrine Cancers

October 8, 2008 - Neotropix®, Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced that it has begun enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010 (SVV-001), a tumor-selective naturally-occurring oncolytic virus. Neotropix® also announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) of NTX-010 for the treatment of neuroendocrine tumors.

After reviewing safety data from the current Phase I dose escalation study, conducted in neuroendocrine cancer patients, and as previously defined in the on-going protocol, the study is open to recruit more patients at the highest dose planned for long-term drug development. The expansion phase of the study allows the clinical sites to enroll additional patients meeting the enrollment criteria to evaluate safety and efficacy across a range of related cancers. To date, the Company has tested this clinical candidate, primarily in patients with carcinoid cancers of multiple origins, small cell cancer, including lung cancer, pancreatic islet cancer, and neuroendocrine cancers of unknown origin... Neotropix' Press Release -